Seratrodast is a selective thromboxane A2 (TXA2) receptor antagonist used primarily for the treatment of bronchial asthma. It works by blocking the action of TXA2, a potent bronchoconstrictor and pro-inflammatory mediator, thereby reducing airway hyperresponsiveness, bronchoconstriction, and inflammation. It is considered a controller medication for asthma management.
Adult: 80 mg twice daily, after morning and evening meals.
Note: Administer orally with water, preferably after food to improve tolerability and reduce gastrointestinal side effects. Tablet should be swallowed whole, not chewed or crushed. Must be taken regularly for continuous prophylactic effect, even when asymptomatic.
Seratrodast competitively and selectively antagonizes the thromboxane A2/prostaglandin H2 (TP) receptor. TXA2 is an arachidonic acid metabolite released from activated platelets, macrophages, and other inflammatory cells. In asthma, TXA2 causes potent bronchoconstriction, enhances airway hyperresponsiveness, promotes vascular permeability, and stimulates mucus secretion. By blocking its receptor, seratrodast inhibits these pathophysiological effects.
Pregnancy: Category N (Not classified by US FDA). Animal studies show no direct teratogenicity, but there is insufficient human data. Use only if potential benefit justifies potential risk to the fetus. Not recommended during pregnancy unless clearly needed.
Driving: Seratrodast may cause dizziness or headache in some patients. Patients should be cautioned about operating machinery or driving until they are sure the medication does not affect them adversely.
| Warfarin, Acenocoumarol | Potential increased risk of bleeding due to possible additive effect. Monitor INR closely. | Major |
| Strong CYP2C8 Inhibitors (e.g., Gemfibrozil, Clopidogrel) | May significantly increase seratrodast plasma levels, increasing risk of toxicity (especially hepatotoxicity). Avoid combination or use with extreme caution. | Major |
| CYP2C8 Inducers (e.g., Rifampicin) | May decrease seratrodast plasma levels, reducing efficacy. Dose adjustment may be needed. | Moderate |
| Other Hepatotoxic Drugs (e.g., Paracetamol high dose, Statins, Azole antifungals) | Additive risk of liver injury. Monitor LFTs regularly. | Moderate |
| Aspirin/NSAIDs | No significant pharmacokinetic interaction, but both can cause GI upset. Theoretical pharmacodynamic interaction on platelets is minimal. | Minor |
Same composition (Seratrodast (80mg)), different brands: